NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?

The chemopreventive NO-donating NSAIDs (NO-NSAIDs; NSAIDs with an NO-releasing moiety) modulate PPARdelta and offer the opportunity to revisit the controversial role of PPARdelta in carcinogenesis (several papers report that PPARdelta either promotes or inhibits cancer). This review summarizes the pharmacology of NO-NSAIDs, PPARdelta cancer biology, and the relationship between the two. In particular, a study of the chemopreventive effect of two isomers of NO-aspirin on intestinal neoplasia in Min mice showed that, compared to wild-type controls, PPARdelta is overexpressed in the intestinal mucosa of Min mice; PPARdelta responds to m- and p-NO-ASA proportionally to their antitumor effect (p- > m-). This effect is accompanied by the induction of epithelial cell death, which correlates with the antineoplastic effect of NO-aspirin; and NO-aspirin's effect on PPARdelta is specific (no changes in PPARalpha or PPARgamma). Although these data support the notion that PPARdelta promotes intestinal carcinogenesis and its inhibition could be therapeutically useful, more work is needed before a firm conclusion is reached.